专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市中药公司，其聘 任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，50岁-60岁CFO是市场的中坚力量，占比共计达到44%；60岁以上的CFO占比 为2%；40岁-50岁的CFO群体占比为42%；40岁及以下CFO群体占比为12%。其中，目前仍任职的最年 轻的上市公司CFO年龄38岁，为恩威医药的胡大伟。 从薪酬分布看，A股中药公司CFO年薪平均值为73.09万元。经统计，处于50万以下、50万-100万、100 万以上各区间的人数占比分别为44%、28%、28%。 其中，年薪排行前三的CFO分别为济川药业的严宏泉、以岭药业（维权）的李晨光、东阿阿胶的丁红 岩，三人年薪分别为178.47万元、174万元 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-033 恩威医药股份有限公司 关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称：公司）全资子公司河南信心药业有限公司（以 下简称：信心药业）于近日取得了药品监管部门换发的《药品生产许可证》，现将有 关情况公告如下： 一、换发的《药品生产许可证》基本信息 质量负责人：王珏 企业名称：河南信心药业有限公司 注册地址：郑州市二七区嵩山南路 81 号嵩山园区综合楼南楼第五层楼 有效期至：2025 年 12 月 31 日 编 号：豫 20150079 分类码：AzBz 生产地址和生产范围： 社会信用代码：91410100170007221L 法定代表人：庄严 企业负责人：陈世超 1、婴儿健脾散、冰硼散两个品种已完成委托、受托生产的许可证换发，尚需河南 信心药业有限公司完成生产地址变更及关联变更的备案后方能投入生产； 2、2023 年公司通过重整信心药业，一次性取得了 125 个中成药产品批文，根据公 司制定的信心药业品种发展规划 ...

天眼查商业履历信息显示，恩威医药股份有限公司，成立于2005年，位于昌都市，是一家以从事医药制 造业为主的企业。企业注册资本10289.1887万人民币，实缴资本7069.637717万人民币。公司法定代表人 为薛永江。 通过天眼查大数据分析，恩威医药股份有限公司共对外投资了3家企业，参与招投标项目7次，知识产权 方面有商标信息53条，专利信息7条，此外企业还拥有行政许可6个。 来源：金融界 金融界消息 截至2025年8月5日收盘，恩威医药（301331）报收于36.65元，下跌1.43%，换手率6.87%， 成交量2.27万手，成交金额8350.15万元。 资金流向方面，今日主力资金净流出1371.22万元，占比成交额16.42%。其中，超大单净流出501.46万 元、占成交额6.01%，大单净流出869.76万元、占成交额10.42%，中单净流出流入330.16万元、占成交 额3.95%，小单净流入1041.06万元、占成交额12.47%。 恩威医药最新一期业绩显示，截至2025一季报，公司营业总收入1.96亿元、同比增长7.10%，归属净利 润1630.51万元，同比增长93.56%，扣非净利润1462 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司高级管理人员陈磊保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 恩威医药股份有限公司（以下简称"公司"）副总裁陈磊先生持有公司股份65,118股，占公司总股本比例 0.0633%（占剔除已回购股份后总股本比例0.0644%），计划在本减持计划预披露公告之日起十五个交 易日后的三个月内（窗口期不减持），以集中竞价方式减持公司股份不超过16,279股，占公司总股本比 例0.0158%（占剔除已回购股份后总股本比例0.0161%），若在本减持计划公告日至减持时间区间届满 日期间公司有送股、资本公积金转增股本、配股等股份变动事项，上述拟减持股份数量将进行相应调 整。 恩威医药股份有限公司（以下简称"公司"）于近日收到公司副总裁陈磊先生出具的《关于股份减持计划 的告知函》，现将有关情况公告如下： 4、减持期间：自减持计划公告发布之日起15个交易日后的三个月内（中国证监会、深圳证券交易所相 关法律法规、规范性文件规定不得进行减持的时间除外）。 5、价格区 ...

Core Insights - Jiangnan Yifan disclosed plans to increase its shareholding by no less than 50,000 shares and no more than 100,000 shares [1] - A total of 14 A-share listed companies announced share reductions, including *ST Dongjing, Hanwang Technology, Heyuan Gas, and others [1] Summary of Shareholding Changes - Jiangnan Yifan: Plans to increase shareholding by 50,000 to 100,000 shares [2] - Hanwang Technology: Director Li Zhifeng plans to reduce holdings by up to 0.0525% [2] - Heyuan Gas: Changjiang Capital plans to reduce holdings by up to 2% [2] - Jieya Shares: Shareholder plans to reduce holdings by up to 4.95% [2] - Pioneering Technology: Shareholder Rongke Chuangtou plans to reduce holdings by up to 1% [2] - Xinling Electric: Director Zhang Pengchun plans to reduce holdings by up to 0.40% [2] - Tongda Shares: Shareholder Huasheng Baili plans to reduce holdings by up to 3% [2] - Yuxin Electronics: Hu Xinrui plans to transfer up to 1 million shares to a related party [2] - Jiusheng Electric: Employee representative director Xu Ming plans to reduce holdings by up to 0.07% [2] - Enwei Medical: Vice President Chen Lei plans to reduce holdings by up to 16,279 shares [2] - Wanhua Chemical: Shareholder plans to reduce holdings by up to 0.54% [2] - Haohan Depth: Shareholder Lianchuang Yongqin plans to reduce holdings by up to 2.17% [2] - Jiahua Technology: Shareholder Gongqingcheng Huayun plans to reduce holdings by up to 2% [2] - Weizhi Xiang: Major shareholder Jinhua Sheng plans to reduce holdings by up to 0.43% [2]

Core Viewpoint - On July 31, Jiangnan Yifan disclosed shareholding changes, with 14 A-share listed companies announcing share reductions, while Jiangnan Tufan planned to increase its shareholding [1][2]. Group 1: Shareholding Increases - Jiangnan Tufan's Liu Songyan plans to increase his shareholding by no less than 50,000 shares and no more than 100,000 shares [2]. Group 2: Shareholding Reductions - *ST Dongjing: Shareholder Ningbo Ningju plans to reduce holdings by no more than 2.43 million shares [2]. - Hanwang Technology: Director and senior manager Li Zhifeng intends to reduce holdings by no more than 0.0525% of the company's shares [2]. - Heyuan Gas: Changjiang Capital plans to reduce holdings by no more than 2% of the company's shares [2]. - Jieya Shares: Shareholders plan to reduce holdings by no more than 4.95% of the company's shares [2]. - Pioneering Technology: Shareholder Rongke Chuangtou plans to reduce holdings by no more than 1% of the company's shares [2]. - Xinling Electric: Director and General Manager Zhang Pengchun plans to reduce holdings by no more than 0.40% of the company's shares [2]. - Tongda Shares: Shareholder Huasheng Baili plans to reduce holdings by no more than 3% [2]. - Yuxin Electronics: Hu Xinrui plans to transfer no more than 1 million shares to his concerted action person Li Yun [2]. - Jiusheng Electric: Employee representative director Xu Ming plans to reduce holdings by no more than 0.07% of the company's shares [2]. - Enwei Pharmaceutical: Vice President Chen Lei plans to reduce holdings by no more than 16,279 shares [2]. - Wanhua Chemical: Shareholders plan to reduce holdings by no more than 0.54% of the company's shares [2]. - Haohan Depth: Shareholder Lianchuang Yongqin plans to reduce holdings by no more than 2.17% of the company's shares [2]. - Jiahua Technology: Gongqingcheng Huayun plans to reduce holdings by no more than 2% of the company's shares [2]. - Weizhi Flavor: Shareholder Jinhua Sheng plans to reduce holdings by no more than 0.43% of the company's shares [2].

格隆汇7月31日丨恩威医药(301331.SZ)公布，副总裁陈磊先生持有公司股份65,118股，占公司总股本比 例0.0633%（占剔除已回购股份后总股本比例0.0644%），计划在本减持计划预披露公告之日起十五个 交易日后的三个月内（窗口期不减持），以集中竞价方式减持公司股份不超过16,279股，占公司总股本 比例0.0158%（占剔除已回购股份后总股本比例0.0161%），若在本减持计划公告日至减持时间区间届 满日期间公司有送股、资本公积金转增股本、配股等股份变动事项，上述拟减持股份数量将进行相应调 整。 ...

Core Viewpoint - The company announced that its Vice President, Chen Lei, plans to reduce his shareholding through a centralized bidding method within three months after the pre-disclosure announcement of the reduction plan [1] Group 1: Shareholding Details - Chen Lei holds 65,118 shares, representing 0.0633% of the company's total share capital and 0.0644% of the total share capital after excluding repurchased shares [1] - The planned reduction will not exceed 16,279 shares, which accounts for 0.0158% of the company's total share capital and 0.0161% of the total share capital after excluding repurchased shares [1] Group 2: Reduction Plan - The shares to be reduced are sourced from equity incentive grants, and the reduction price will be determined based on the market price at the time of implementation [1]

证券代码：301331 证券简称：恩威医药 公告编号：2025-032 恩威医药股份有限公司 关于公司高级管理人员减持股份的预披露公告 公司高级管理人员陈磊保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 恩威医药股份有限公司（以下简称"公司"）副总裁陈磊先生持有公司股份 65,118 股，占公司总股本比例 0.0633%（占剔除已回购股份后总股本比例 0.0644%），计划在本减持计划预披露公告之日起十五个交易日后的三个月内（窗 口期不减持），以集中竞价方式减持公司股份不超过 16,279 股，占公司总股本比 例 0.0158%（占剔除已回购股份后总股本比例 0.0161%），若在本减持计划公告 日至减持时间区间届满日期间公司有送股、资本公积金转增股本、配股等股份变 动事项，上述拟减持股份数量将进行相应调整。 恩威医药股份有限公司（以下简称"公司"）于近日收到公司副总裁陈磊先 生出具的《关于股份减持计划的告知函》，现将有关情况公告如下： 二、减持计划内容 | 股东名称 | 职务 | | | 占 ...

Core Viewpoint - The antiviral oral liquid market is experiencing significant growth driven by the rising incidence of viral diseases and increasing health awareness among consumers, with a projected market size increase from 1.1 billion yuan in 2020 to 1.469 billion yuan in 2024, reflecting a compound annual growth rate of 7.5% [1][12]. Industry Overview - Antiviral oral liquids are common traditional Chinese medicine formulations, primarily composed of ingredients like Banlangen, Shigao, and Lugen, used for treating viral infections such as influenza and respiratory infections [3][5]. - The industry has evolved since the 1980s, transitioning from basic herbal formulations to more sophisticated products due to technological advancements, leading to improved efficacy and safety [5]. Market Dynamics - The demand for antiviral oral liquids is increasing due to the high prevalence of viral diseases and an aging population, alongside a shift in consumer perception of these products as essential for daily health protection [1][12]. - The rise of e-commerce platforms has further facilitated market growth by providing convenient access to these products [1][12]. Industry Chain - The industry chain consists of upstream raw material cultivation, production equipment, and packaging materials; midstream involves the manufacturing of antiviral oral liquids; and downstream includes sales through hospitals, pharmacies, clinics, and e-commerce platforms [8]. Competitive Landscape - The market is becoming increasingly competitive with numerous companies entering the field, necessitating continuous innovation and marketing efforts to stand out [13]. - Key players in the industry include ST Xiangxue, China Resources Sanjiu, Kangyuan Pharmaceutical, and others, each with unique product offerings and market strategies [1][13]. Development Trends - There is significant growth potential in the central and rural markets, where the penetration of antiviral oral liquids is currently low due to insufficient medical resources [21]. - Future innovations in nanotechnology and targeted drug delivery systems are expected to enhance product efficacy and reduce side effects, driving further advancements in the industry [22]. - The market is likely to see increased concentration as leading companies leverage technology and brand development to capture larger market shares, while new entrants may adopt innovative strategies to compete [23].